Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.49 |
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531709 | 0.88 | EGLN1 (0.64) | EGLN1CNR1CNR2ALKBH1 | |
| SCHEMBL3410878 | 0.83 | EGLN1 (0.63) | EGLN1CNR1CNR2TACR3 | |
| SCHEMBL14809600 | 0.79 | EGLN1 (0.44) | EGLN1TACR3ALKBH1HDAC3HDAC1 | |
| SCHEMBL3409150 | 0.75 | EGLN1 (0.56) | EGLN1CNR1CNR2HDAC3HDAC1 | |
| SCHEMBL3409230 | 0.74 | EGLN1 (0.55) | EGLN1CNR1CNR2GPR142 | |
| SCHEMBL3409730 | 0.73 | EGLN1 (0.61) | EGLN1CNR1CNR2TACR3HDAC3 | |
| SCHEMBL3410582 | 0.71 | EGLN1 (0.64) | EGLN1CNR1CNR2TACR3HDAC3 | |
| SCHEMBL3408179 | 0.70 | EGLN1 (0.61) | EGLN1CNR1CNR2TACR3 | |
| SCHEMBL3408688 | 0.70 | EGLN1 (0.48) | EGLN1CNR1CNR2 | |
| SCHEMBL4530398 | 0.70 | EGLN1 (0.50) | EGLN1HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885CNR1 692/4885CNR2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.